New treatment combination improves outcomes for small cell bladder and prostate cancer patients

  • Post author:
  • Post category:uncategorized

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.